Cardiovascular Market Research Reports & Industry Analysis
Variations in heart size and position within the chest may be related to age, body size, shape, weight, or pathologic conditions of the heart and other nearby structures.
There has been considerable study into the role of inflammation in heart disease. Researchers have found the first direct evidence that reducing inflammation in coronary arteries decreases the risk of heart attacks as much as reducing cholesterol levels. This finding offers a new approach to preventing heart disease. Two studies showed that inflammation of the arteries can be reduced by more aggressive use of statins. New drugs that target inflammation that are measured by a marker called Creactive rotein (CRP) could have a large impact on cardiovascular health as well as a large financial gain for companies developing these products.
Cardiovascular Industry Research & Market Reports
-
Antisense & RNAi Therapeutics Market Report by Technology (RNA Interference, Antisense RNA), Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others), Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, and Others), and Region 2025-2033
... during 2025-2033. The market is experiencing steady growth driven by the increasing prevalence of genetic and chronic diseases globally necessitates innovative treatments, supportive regulatory environments across major markets to expedite the approval and commercialization of ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Atrial Fibrillation Devices
... at a CAGR of 12.0% over the analysis period 2024-2030. EP Ablation Catheters, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$4.8 Billion by the end ... Read More
-
Stroke Management
... CAGR of 5.3% over the analysis period 2024-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$35.9 Billion by the end of the analysis ... Read More
-
Congestive Heart Failure (CHF) Treatment Devices
... reach US$37.9 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Implantable Cardioverter Defibrillators, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and ... Read More
-
Acute Ischemic Stroke Diagnosis and Treatment
... reach US$3.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Computed Tomography, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach ... Read More
-
Statins
... 1.8% over the analysis period 2024-2030. Synthetic, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth in ... Read More
-
Heart Valve Repair and Replacement Devices
... reach US$43.1 Billion by 2030, growing at a CAGR of 16.0% over the analysis period 2024-2030. Replacement Devices, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Heart Failure Drugs
... at a CAGR of 12.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR The Heart Failure Drugs market in the U.S. ... Read More
-
Angina Pectoris Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of ... Read More
-
Cardiovascular Drugs
... CAGR of 3.4% over the analysis period 2024-2030. Anticoagulants, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$57.7 Billion by the end of the analysis period. ... Read More
-
Cardiovascular Disease Monitoring and Diagnostic Devices
... reach US$3.6 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. ECG Systems, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach ... Read More
-
Aortic Endografts
... CAGR of 3.7% over the analysis period 2024-2030. Abdominal Aortic Grafts, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.4 Billion by the end of the ... Read More
-
Angiography Devices
... CAGR of 3.9% over the analysis period 2024-2030. Angiography Systems, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.8 Billion by the end of the analysis ... Read More
-
Dilated Cardiomyopathy Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$258.2 Million by ... Read More
-
Perfusion Systems
... CAGR of 4.4% over the analysis period 2024-2030. Cardiopulmonary Perfusion Systems, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$671.0 Million by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Patient Monitoring Devices
... at a CAGR of 7.5% over the analysis period 2024-2030. Blood Glucose, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$23.2 Billion by the end of ... Read More
-
Embolotherapy
... 7.7% over the analysis period 2024-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth ... Read More
-
Cardiovascular and Soft Tissue Repair Patches
... reach US$8.3 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. ePTFE, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$5.0 ... Read More
-
Cardiovascular Ultrasound Systems
... at a CAGR of 5.1% over the analysis period 2024-2030. 2D, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.1 Billion by the end of the ... Read More
-
C-Reactive Protein Testing
... at a CAGR of 1.7% over the analysis period 2024-2030. Immunoturbidimetric Assay, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Cardiology IT Workflow Solutions
... 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Cloud, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$1.1 Billion by the end ... Read More
-
Cardiovascular Repair and Reconstruction Devices
... Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Cardiovascular Grafts, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.3 Billion ... Read More
Research Assistance
